A review on exosomes application in clinical trials: perspective, questions, and challenges.
Rezaie J, Feghhi M, Etemadi T. · 2022
Read A review on exosomes application in clinical trials: perspective, questions, and challenges. by Rezaie J, Feghhi M, Etemadi T. (2022) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc9483361.txt.
Introduction
Rezaie, Feghhi, and Etemadi review the use of exosomes in clinical trials. Exosomes are tiny vesicles that carry active molecules between cells. They shape many normal and disease processes. Trials now test them as treatments and as test markers.
The authors surveyed two decades of work on exosome trials. Main uses include biomarker tests and cell-free therapy. Drug delivery and cancer vaccines are further uses. Blood is the top source for biomarker work. Mesenchymal stem cells and dendritic cells lead as therapy sources. Stem cell exosomes often target inflammation and drug carriage. Dendritic cell exosomes aim to stir anti-cancer responses. Hurdles include open questions on exosome kinetics in the body. Trial products must also meet strict manufacturing rules, the authors note.
Catalog record
| CREATOR | Rezaie J, Feghhi M, Etemadi T. |
|---|---|
| YEAR | 2022 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 51 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
A review on exosomes application in clinical trials: perspective, questions, and challenges By Jafar Rezaie, Maryam Feghhi, Tahereh Etemadi Published in: Cell Communication and Signaling : CCS DOI: 10.1186/s12964-022-00959-4 ABSTRACT Abstract Background Exosomes are progressively known as significant mediators of cell-to-cell communication. They convey active biomolecules to target cells and have vital functions in several physiological and pathological processes, and show substantial promise as novel treatment strategies for diseases. Methods In this review study, we studied numerous articles over the past two decades published on application of exosomes in different diseases as well as on perspective and challenges in this field. Results The main clinical application of exosomes are using them as a biomarker, cell-free therapeutic agents, drug delivery carriers, basic analysis for exosome kinetics, and cancer vaccine. Different exosomes from human or plant sources are utilized in various clinical trials. Most researchers used exosomes from the circulatory system for biomarker experiments. Mesenchymal stem cells (MSCs) and dendritic cells (DCs) are two widely held cell sources for exosome use. MSCs-derived exosomes are commonly used for inflammation treatment and drug delivery, while DCs-exosomes are used to induce inflammation response in cancer patients. However, the clinical application of exosomes faces various questions and challenges. In addition, translation of exosome-based clinical trials is required to conform to specific good manufacturing practices (GMP). In this review, we summarize exosomes in the clinical trials according to the type of application and disease. We also address the main questions and challenges regarding exosome kinetics and clinical applications. Conclusions Exosomes are promising platforms for treatment of many diseases in clinical trials. This exciting field is developing hastily, understanding of the underlying mechanisms that direct the various observed roles of exosomes remains far from complete and needs further multidisciplinary research in working with these small vesicles. [Figure: Video Abstract] Supplementary Information The online version contains supplementary material available at 10.1186/s12964-022-00959-4. Keywords: Exosomes, Extracellular vesicles, Clinical trials, Exosome therapy BACKGROUND Extracellular vesicles (EVs) include heterogeneous cell-derived vesicles produced by most cells via diverse mechanisms that contribute to cell-to-cell communication by transferring biological signals such as many non-coding RNAs, coding RNAs, DNA strands, portions, and lipids to counterpart cells [1]. EVs can also deliver their cargo/ messages to target cells by many body fluids including, the circulating system, saliva, cerebrospinal fluid (CSF), urine, milk, and bronchoalveolar lavage fluid (BALF) [2]. Once delivered to target cells, EVs can regulate the fate and morphology of recipient cells by driving different signaling pathways, which may result in either normal physiology or pathogenesis depending on the origin of EVs and the state of cells. Emerging evidence suggests that EVs play pivotal roles in a range of cellular processes including, proliferation, growth, development, angiogenesis, immunomodulation, infection, metastasis, reprogramming and remodeling [3–6]. Three major subclasses of EVs have been documented including microvesicles (MVs) or ectosomes, apoptotic bodies, and exosomes [7, 8] (Fig. 1) (Table 1). The term MVs refers to EVs that are generated from the plasma membrane with a size range 100–1000 nm via a complex mechanism known as shedding or blebeling of the plasma membrane resembling a virus outward budding a cellular membrane [7, 8]. Another EVs that have increasingly attracted scientists' attention is exosomes with a size range 30–150 nm [7, 8]. These vesicles have been reported are also heterogeneous both in size and cargo consequently functioning diversely on target cell signaling [9]. The origin of exosomes is vesicles involved in the endocytosis pathway were a type of late endosomes named multivesicular bodies (MVBs) begin to generate exosomes. Recent progress in EVs has shown that exosomes biogenesis may interplay with another endomembrane system to maintain cellular homeostasis [10]. For example, crosstalk between exosomes signaling pathway and autophagy has been reported in normal physiology and several diseases [11]. Over the past decade, there has been a dramatic increase in translational medicine of exosomes seeking to improve the outcome of therapies and focus on precision medicine [12, 13]. Exosomes represent unique properties that engrossed the researchers to use them for the treatment of many diseases including degenerative disorders and cancers [14, 15]. Until now, many clinical trials are carried out using exosomes from different sources for various diseases. Although this approach is interesting and clinical trials showed satisfactory outcomes, there are some challenges and limitations in this field and further investigations are needed to validate these results and introduce a gold standard for exosomes-based studies. Methodical examination of the efficiency and safety of exosomes needs determination of their individuality and purity. The International Society for Extracellular Vesicles (ISEV) instigated the standardization of EVs isolation and characterization procedures by releasing MISEV guidelines in 2014 and 2018, which discuss the most essential characteristics that must be considered in EVs-based studies [16, 17]. Furthermore, the EV-TRACK database was established in 2017 that offers researchers to credit their purification and characterization methods before publication and make recommendations on possible limitations of the experimental plan (https://evtrack.org/about.php). This paper is an overview of the potential clinical application of exosomes and the challenges and questions in this roadmap. [Figure: Extracellular vesicles (EVs) biogenesis. Two main subclasses of EVs are exosomes and microvesicles (MVs). Exosomes biogenesis is complex and occurs inside multivesicular bodies (MVBs) located in the cytoplasm. ESCRT complexes and different molecules contribute to loading, sorting and forming exosomes in ATP dependent and independent manners. Exosomes cargo come from Golgi apparatus, the endosomal pathway, and the cytoplasm. Rab proteins mediate intracellular trafficking of endosomal compartments and exosomes. MVBs have been reported to fuse with either plasma membrane, lysosomes or amphisoms. When MVBs fuse with the plasma membrane, exosomes are released into the extracellular milieu. There is evidence that exosomes biogenesis pathway may crosstalk with autophagy flux. MVBs may fuse with autophagosomes and form the hybrid vesicles known ‘’Amphisomes’’, which finally fuse with the plasma membrane or lysosomes. MVs are larger than exosomes and formed from the plasma membrane through the outward budding and shedding process. EVs can affect the target cells' fate and signaling pathways in three possible ways comprising endocytosis, receptor-ligand interaction, and direct fusion with the plasma membrane] [Table: Types of extracellular vesicles] EXOSOMES The term exosomes refer to membrane-bound vesicles released from many cells into the extracellular matrix [7, 18]. The main idea is that these nano-particles are generated inside the cells, within the MVBs, by the invagination of the membrane of MVBs, which leads to the generation of intraluminal vesicles (ILVs) inside MVBs [7, 18] (Fig. 1). These vesicles may be named pre-exosomes, which can be secreted out of cells following the fusion of MVBs with the cellular membrane; now there are known as exosomes [7, 18]. Always MVBs do not expel ILVs out of cells, rather they may fuse with the lysosomes and subsequently ILVs and their cargo are degraded for recycling and reuse for cellular homeostasis [7, 18]. In addition, there is evidence that MVBs may fuse with the autophagosomes of the autophagy pathway, and generate hybrid vesicles known as ‘’Amphisomes’’, subsequently, amphisomes may now fuse with the plasma membrane and secrete exosomes with other cargo [19, 20]. Understanding how and why MVBs fuse with different membranes has been a long-standing goal because it is critical to discriminate heterogeneity in exosomes, and relevant physiological consequences, regulate